CMPXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Compass Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$0.83−0.03 (-2.91%)
Close on Oct 19, 2026
- Market cap
- $155.98M
- P/E (TTM)
- –
- Dividend yield
- –
Compass Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Compass Therapeutics | Industry median |
|---|---|---|
| Market Cap | $150.37M | $164.85M |
| Enterprise Value | -$29.51M | $87.06M |
| PB Ratio | 0.91 | 2.03 |
| P/TBV Ratio | 0.91 | 2.31 |
Income (trailing twelve months)
| Measure | Compass Therapeutics | Industry median |
|---|---|---|
| Operating Income | -$81.09M | -$21.44M |
| Net Income | -$73.45M | -$22.46M |
| EBITDA | -$81.01M | -$16.91M |
| EPS (Diluted) | -$0.39 | -$0.83 |
Returns
| Measure | Compass Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -56.7% | -53.1% |
| Return on Assets (ROA) | -47.9% | -41.0% |
| Return on Capital Employed (ROCE) | -46.6% | -37.8% |
Balance sheet
| Measure | Compass Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $179.88M | $62.42M |
| Net Cash (Debt) | $179.88M | $15.68M |
| Net Cash Per Share | $1.00 | $0.66 |
| Equity (Book Value) | $166.05M | $48.79M |
| Book Value Per Share | $0.92 | $1.36 |
| Tangible Book Value | $166.05M | $23.06M |
| Working Capital | $164.76M | $75.77M |
Financial position
| Measure | Compass Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 11.22 | 3.30 |
| Quick Ratio | 11.15 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Compass Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$56.11M | -$12.35M |
| Capital Expenditures | -$265.00K | -$1.06M |
| Free Cash Flow | -$56.38M | -$20.28M |
| FCF Per Share | -$0.31 | -$0.42 |
Efficiency
| Measure | Compass Therapeutics | Industry median |
|---|---|---|
| Profits Per Employee | -$1.88M | -$703.34K |
| Employee Count | 39 | 74 |
Dividends and yields
| Measure | Compass Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -48.8% | -22.7% |
| FCF Yield | -37.5% | -9.07% |
Shares
| Measure | Compass Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 180,088,000 | 58,179,650 |
| Shares Change (YoY) | 31.8% | 11.1% |
| Shares Change (QoQ) | 0.00% | 0.54% |
| Float | 132,669,000 | 49,173,100 |
| Shares Held by Insiders | 26.3% | 11.6% |
| Shares Held by Institutions | 92.0% | 59.4% |
Scores
| Measure | Compass Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -0.12 | -0.24 |
| Piotroski F-Score | 3 | 4 |
Calculated by StockData from Compass Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.